Medicare Enrolled

Dr. Susan Mathew, M .D.

Optician · Sugar Land, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
1429 HIGHWAY 6 STE 209, Sugar Land, TX 77478
8325001395
In practice since 2010 (15 years)
NPI: 1356651244 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Mathew from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mathew? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Mathew

Dr. Susan Mathew is an optician in Sugar Land, TX, with 15 years in practice. Based on federal Medicare data, Dr. Mathew performed 114,032 Medicare services across 1,022 unique beneficiaries.

Between the years covered by Open Payments, Dr. Mathew received a total of $55,262 from 42 pharmaceutical and/or device companies across 978 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Mathew is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 15 years in practice▲ Top 1% volume in TX$ $55,262 industry payments

Medicare Practice Summary

Medicare Utilization ↗
114,032
Medicare services
Top 1% in TX for optician
1,022
Unique beneficiaries
$5
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~7,602 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Certolizumab injection (Cimzia)98,800$4$30
Golimumab infusion (Simponi Aria)12,883$10$76
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle494$55$218
Office visit, established patient (30-39 min)440$88$157
Steroid injection (triamcinolone)250$1$30
Blood draw (venipuncture)182$8$11
Sed rate test (inflammation marker)174$3$21
Complete blood count (CBC) with differential168$8$26
C-reactive protein test (inflammation marker)157$5$29
Comprehensive metabolic blood panel151$10$50
Administration of chemotherapy into vein, 1 hour or less85$89$600
Drug injection, under skin or into muscle52$10$70
New patient office visit, complex (60-74 min)49$141$300
Joint injection, major joint41$48$188
Uric acid level test28$4$21
X-ray of hand, minimum of 3 views21$28$105
Creatine kinase (cardiac enzyme) level, total21$6$26
Office visit, established patient, complex (40-54 min)19$130$208
Office visit, established patient (20-29 min)17$61$112
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
11.3% high complexity
87.5% medium
1.3% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$55,262
Total received (2018-2024)
Avg $7,895/year across 7 years
Top 5% in TX for optician
42
Companies
978
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$29,794 (53.9%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$17,425 (31.5%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$8,043 (14.6%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$9,708
2023
$3,488
2022
$5,033
2021
$5,317
2020
$7,917
2019
$20,858
2018
$2,942

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Mallinckrodt Enterprises LLC
$17,499
Mallinckrodt Hospital Products Inc.
$12,361
UCB, Inc.
$5,788
Janssen Biotech, Inc.
$3,045
ABBVIE INC.
$2,717
Amgen Inc.
$2,205
PFIZER INC.
$1,386
Horizon Therapeutics plc
$1,352
Celgene Corporation
$1,328
Novartis Pharmaceuticals Corporation
$1,296
Lilly USA, LLC
$929
GlaxoSmithKline, LLC.
$635
AstraZeneca Pharmaceuticals LP
$460
AbbVie, Inc.
$448
GENZYME CORPORATION
$419
Nevro Corp.
$391
Radius Health, Inc.
$379
E.R. Squibb & Sons, L.L.C.
$359
AbbVie Inc.
$344
Aurinia Pharma U.S., Inc.
$338
ANI Pharmaceuticals, Inc.
$255
Alexion Pharmaceuticals, Inc.
$154
Mallinckrodt LLC
$131
Johnson & Johnson Health Care Systems Inc.
$129
MEDEXUS PHARMA, INC.
$128
Teva Pharmaceuticals USA, Inc.
$120
Horizon Pharma plc
$113
Genentech USA, Inc.
$93
Boehringer Ingelheim Pharmaceuticals, Inc.
$79
SANOFI-AVENTIS U.S. LLC
$77
Kiniksa Pharmaceuticals, Ltd.
$52
Sandoz Inc.
$45
Gilead Sciences, Inc.
$43
Takeda Pharmaceuticals U.S.A., Inc.
$26
Ultragenyx Pharmaceutical Inc.
$25
Medtronic, Inc.
$20
Sobi, Inc
$20
Antares Pharma, Inc.
$17
Celltrion USA Inc.
$16
Bioventus LLC
$15
IBSA Pharma Inc.
$14
Janssen Pharmaceuticals, Inc
$13
Top 3 companies account for 64.5% of total payments
Associated products mentioned in payments ›
ACTHAR · AJOVY · AMJEVITA · Actemra · Arcalyst · BENLYSTA · Bimzelx · COLOGUARD · COSENTYX · CYLTEZO · Cimzia · Crysvita · DUEXIS · DUROLANE · EUCRISA · EVENITY · EVUSHELD · Enbrel · FORTEO · HUMIRA · HYRIMOZ · Humira · ILARIS · INTELLIS ADAPTIVESTIM · JARDIANCE · KEVZARA · KRYSTEXXA · Kineret · LUPKYNIS · LYRICA · ORENCIA · Otezla · Otrexup · PENNSAID · PURIFIED CORTROPHIN GEL · Prolia · QULIPTA · RAYOS · REMICADE · RHEUMATOID ARTHRITIS DISEASE · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · Senza · Senza Spinal Cord Stimulation System · Strensiq · TALTZ · TAVNEOS · TEFLARO · TRELEGY ELLIPTA · TREMFYA · Tavneos · Tirosint · Trintellix · Tymlos · UBRELVY · Uloric · VIMOVO · VRAYLAR · XARELTO · XELJANZ · YUFLYMA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (54%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in optician and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 5% for optician in TX.

Equivalent to $48 per 100 Medicare services performed
Looking for a optician in Sugar Land?
Compare opticians in the Sugar Land area by procedure volume, costs, and industry payment transparency.
Browse opticians nearby

Geographic Context

Opticians within 10 mi
440
Per 100K population
51.2
County median income
$113,409
Nearest hospital
ST LUKE'S SUGAR LAND HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Mathew is a mixed practice specialist, with above-average Medicare volume (top 1% in TX), and high industry engagement (speaking/promotional, top 5%), with 15 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Mathew experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Mathew performed 98,800 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Mathew receive payments from pharmaceutical companies?
Yes. Dr. Mathew received a total of $55,262 from 42 companies across 978 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mathew's costs compare to other opticians in Sugar Land?
Dr. Mathew's average Medicare payment per service is $5. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mathew) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →